Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Cipla had earlier invested € 15 million in Ethris in 2022
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Subscribe To Our Newsletter & Stay Updated